ABAX Abaxis, Inc. (delisted)

Infolab to Sell and Distribute the Piccolo Chemistry Analyzer and the Medical Reagent Discs UNION CITY, Calif., July 20 /PRNewswire-FirstCall/ -- Abaxis, Inc. (NASDAQ:ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that the Company has entered into a formal distribution agreement with Infolab, Inc., one of the oldest independent laboratory companies in the U.S. Infolab, Inc. will sell and distribute the Piccolo(R) chemistry analyzer and the complete line of Abaxis' reagent discs within the U.S. medical market. Clint Severson, chairman and chief executive officer of Abaxis commented, "We are pleased to add Infolab to the growing distribution channel for the Piccolo chemistry analyzer system. We believe that Infolab can effectively develop the laboratory segment of the market and provide penetration into another strong component of the overall domestic medical market." Chris Bernard, vice president of Sales and Marketing for Abaxis, commented, "This agreement with Infolab addresses an important strategic goal for Abaxis. Their ability to sell capital equipment, specific to the physician office laboratory is well known in the industry. We believe that on a long-term basis, Infolab will help us to establish a growing presence in the laboratory segment of the business. We look forward to working closely with the Infolab team." About Infolab Infolab, founded in 1968, specializes in equipment and supplies for the clinical laboratory. Its clients are hospitals, physician offices, research facilities, universities, and other facilities performing clinical laboratory testing. Infolab has six distribution centers employing more than 200 full-time personnel in sales, service, and technical support positions. Infolab's service area includes the mid-Atlantic states, the southeastern states, Florida, the mid-western states, and the southwestern states. There are six distribution centers in Florida, Georgia, Indiana, Mississippi, North Carolina and Texas. About Abaxis Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 6.9 kilogram (15 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 14 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer. This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may", "believes", "projects", "expects", or "anticipates", and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to, risks and uncertainties related to fluctuations in the Company's share price, the market acceptance of the Company's products and the continuing development of its products, required United States Food and Drug Administration ("FDA") clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with entering the human diagnostic market on a larger scale, risks related to the protection of the Company's intellectual property or claims of infringement of intellectual property asserted by third parties, risks involved in carrying of inventory, risks associated with the ability to attract, train and retain competent sales personnel, general market conditions, competition and other risks detailed from time to time in Abaxis' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statement was made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements. Contact: Clint Severson Lytham Partners, LLC Chief Executive Officer Joe Dorame, Joe Diaz or Robert Blum Abaxis, Inc. 602-889-9700 510-675-6500 DATASOURCE: Abaxis, Inc. CONTACT: Clint Severson, Chief Executive Officer of Abaxis, Inc., +1-510-675-6500; or Joe Dorame, Joe Diaz or Robert Blum, all of Lytham Partners, LLC, +1-602-889-9700, for Abaxis, Inc.

Copyright